Skip to main content

Table 3 Univariate analysis of overall survival after diagnosis of sPAP in MDS

From: Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan

Variable at diagnosis of sPAP

(n)

75% of OS (months)

50% of OS (months)

HR (95% CI)

Pvalue

Age: 51 yrs or younger

16

8

16

  

   Older than 52 yrs

15

10

15

1.29 (0.48-3.41)

0.607

Gender: Male

19

10

16

  

    Female

12

11

21

1.12 (0.43-2.94)

0.804

MDS group: mild

13

10

15

  

      severe

18

11

16

1.11 (0.42-2.95)

0.830

Symptoms: (-)

5

26

26

  

     (+)

26

6

15

1.50 (0.33-6.65)

0.592

Dx procedure: Bronchoscopy

23

11

13

  

      Surgical biopsy

8

15

26

0.69 (0.23-2.04)

0.507

Respiratory failure: (-)

21

11

26

  

         (+)

10

5

10

2.18 (0.77-6.22)

0.142

Use of corticosteroid: (-)

16

16

80

  

         (+)

15

10

13

3.20 (1.09-9.38)

0.034

Serum KL-6 (U/ml): < 1960

16

13

26

  

         1960 ≦

15

5

15

1.52 (0.58-4.00)

0.389

Serum SP-D (ng/ml): < 147

15

10

26

  

         147 ≦

15

8

15

1.80 (0.62-5.22)

0.278

Serum SP-A (ng/ml): < 79

16

11

26

  

         79 ≦

14

5

15

2.79 (0.965-8.06)

0.058

%VC: 87 ≦

11

15

34

  

    < 87

11

8

15

3.27 (0.79-13.52)

0.101

FEV1%: 86 ≦

12

8

16

  

     < 86

10

13

34

0.52 (0.14-1.87)

0.322

%DLco: 44 ≦

9

21

34

  

     < 44

8

5

13

9.98 (1.03-96.11)

0.046

  1. CI indicates confidence interval; OS, overall survival; DLco, diffusing capacity of the lung for carbon monoxide; Dx, diagnosis; FEV, forced expiratory volume; HR, hazard ratio; KL-6, krebs von den lungen-6; MDS, myelodysplastic syndrome; SP-A, surfactant protein -A; sPAP, secondary pulmonary alveolar proteinosis; SP-D, surfactant protein -D; VC, vital capacity.